Last checked at 26 Sep 2016 16:00
26 September 2016 16:00
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.
The change in interest relates to the vesting of an award of AstraZeneca American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca Restricted Share Plan.
One ordinary share equals two ADSs.
After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Bohen has become beneficially entitled to and has received 12,385 ADSs into a personal brokerage account.
For tax purposes, the fair market value of the shares at vest was $33.97 per ADS being the closing price on the last trading day preceding the vesting day.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| Sean Bohen
| ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Executive Vice-President, Global Medicines Development and Chief Medical Officer | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| AstraZeneca PLC | ||||
b)
| LEI
| Not applicable | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
| ||||
b)
| Nature of the transaction
| Acquisition of AstraZeneca American Depositary Shares pursuant to the vesting of an award under the AstraZeneca Restricted Share Plan | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
| Not applicable - single transaction
| ||||
e)
| Date of the transaction
| 26 September 2016 | ||||
f)
| Place of the transaction
| New York | ||||
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
|
|
|
Neil Burrows
| UK/Global
| +44 203 749 5637
|
Vanessa Rhodes
| UK/Global
| +44 203 749 5736
|
Karen Birmingham
| UK/Global
| +44 203 749 5634
|
Rob Skelding
| UK/Global
| +44 203 749 5821
|
Jacob Lund
| Sweden
| +46 8 553 260 20
|
Michele Meixell
| US
| +1 302 885 2677
|
Investor Relations | ||
UK | ||
Thomas Kudsk Larsen
|
| +44 203 749 5712
|
Craig Marks
| Finance, Fixed Income, M&A
| +44 7881 615 764
|
Nick Stone
| Respiratory & Autoimmunity
| +44 203 749 5716
|
Henry Wheeler
| Oncology
| +44 203 749 5797
|
Christer Gruvris | Infection & Neuroscience | +44 203 749 5711 |
US | ||
Lindsey Trickett
| Cardiovascular & Metabolic Diseases
| +1 240 543 7970
|
Mitchell Chan
| Oncology
| +1 240 477 3771
|
Toll-free | +1 866 381 7277 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-